Organigram Holdings Inc. Operating CF/Net income

Operating CF/Net income of OGI for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating CF/Net income growth rates and interactive chart. Calculated as operating cash flow divided by net income to common shareholders. Also called income quality ratio. A ratio of greater than 1.0 usually indicates high-quality income, while a ratio of less than 1.0 indicates low-quality.


Highlights and Quick Summary

  • Operating CF/Net income for the quarter ending February 28, 2022 was 0.16 (a -97.76% decrease compared to previous quarter)
  • Year-over-year quarterly Operating CF/Net income decreased by -94.22%
  • Annual Operating CF/Net income for 2021 was 0.23 (a -35.48% decrease from previous year)
  • Annual Operating CF/Net income for 2020 was 0.36 (a -91.47% decrease from previous year)
  • Annual Operating CF/Net income for 2019 was 4.2 (a -657.46% decrease from previous year)
  • Twelve month Operating CF/Net income ending February 28, 2022 was 0.79 (a 101.73% increase compared to previous quarter)
  • Twelve month trailing Operating CF/Net income increased by 129.46% year-over-year
Trailing Operating CF/Net income for the last four month:
28 Feb '22 30 Nov '21 31 Aug '21 31 May '21
0.79 0.39 0.23 0.35
Visit stockrow.com/OGI for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating CF/Net income of Organigram Holdings Inc.

Most recent Operating CF/Net incomeof OGI including historical data for past 10 years.

Interactive Chart of Operating CF/Net income of Organigram Holdings Inc.

Organigram Holdings Inc. Operating CF/Net income for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 0.16
2021 6.94 0.28 2.69 0.17 0.23
2020 -0.01 0.7 -0.11 1.67 0.36
2019 15.84 0.69 -0.31 1.14 4.2
2018 -0.5 -0.7 -0.75
2017 0.82
2016 -2.56

Business Profile of Organigram Holdings Inc.

Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic